co-cultured autologous HBVs+ HCC organoids with T cells and evaluated the ability of CD39+ HBVs-CAR-T and CD39+ personalized tumor-reactive CD8+ T cells to induce apoptosis of HCC organoids, validating that CD39+ has huge potential as a biomarker for the enrichment of cytotoxic T cells and patient stratification in CAR-T therapy (80). This evidence concerns the gene CD8A and neoplasm.